In addition, our preclinical studies also showed that the combination of DT2216 with various targeted-therapeutic agents (such as BCL-2 inhibitors, mTOR inhibitors, and KRAS G12C inhibitors) as well as other conventional chemotherapeutic agents (such as gemcitabine, irinotecan, and azacytidine) can synergistically kill various cancer and leukemic cells [5, 10, 12–15]. The gene discussed is KRAS; the disease is cancer.